Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
7.91
-0.03 (-0.38%)
May 13, 2025, 4:00 PM - Market closed
Immunome Revenue
Immunome had revenue of $2.93M in the quarter ending March 31, 2025, with 184.35% growth. This brings the company's revenue in the last twelve months to $10.94M, down -13.76% year-over-year. In the year 2024, Immunome had annual revenue of $9.04M, down -35.50%.
Revenue (ttm)
$10.94M
Revenue Growth
-13.76%
P/S Ratio
47.44
Revenue / Employee
$92,695
Employees
118
Market Cap
688.27M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IMNM News
- 1 day ago - Immunome Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 11 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 27 days ago - Immunome: Transformed Pipeline Offers Multiple Catalysts - Seeking Alpha
- 5 weeks ago - Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire
- 7 weeks ago - Immunome Reports Full Year 2024 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC - Business Wire
- 2 months ago - Immunome to Present at Upcoming March Conferences - Business Wire
- 3 months ago - Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - Business Wire